Retatrutide cannot be marketed for human use unless it has gone through the MHRAs approval process , which includes safety and efficacy trials
Summary: Researchers identified a critical safety concern linking popular glucagon-like peptide-1 (GLP-1) receptor agonists to significant hypotensive episodes, which include severe dizziness, fainting, and dangerous falls
The mean age of participants was 55 years, and the mean duration of diabetes was 9 years
With the right training, nutrition, and clinical support, they can absolutely be maintained during GLP-1 therapy
Whats new is actively prescribing medications whose primary indication is metabolic (obesity, diabetes) but that also have psychiatric effects
Participants receiving the highest doses saw significant weight loss, with some shedding nearly a third of their body weight, outcomes comparable to bariatric surgery